Feasibility by indication
What makes a trial feasible — indication by indication.
Every indication has its own feasibility traps — biomarker gating, site saturation, screen fails. Each page lays out what drives go/no-go, grounded in public data and ready to run against your own protocol.
Feasibility scored across indications.
Solid tumors · Phase I–II heavy
Oncology — solid tumors
Solid-tumor oncology is the most crowded area in clinical research, which makes site competition and patient overlap the dominant feasibility risks.
View feasibility →NSCLC · Phase II–III
Non-small-cell lung cancer (NSCLC)
NSCLC is one of the most actively studied indications, with feasibility dominated by molecular sub-segmentation (EGFR, ALK, KRAS G12C, PD-L1 status).
View feasibility →Breast cancer · Phase II–III
Breast cancer
Breast-cancer feasibility hinges on receptor subtype (HR+/HER2+/triple-negative) and line of therapy.
View feasibility →Type 2 diabetes · Phase II–III
Type 2 diabetes
Type 2 diabetes has a large prevalent population, so the feasibility risk shifts from "are there enough patients" to "can we enroll fast enough against heavy competition and tight eligibility windows." Background-therapy and HbA1c criteria do most of the cohort filtering..
View feasibility →Alzheimer's · Phase II–III
Alzheimer's disease
Alzheimer's feasibility is defined by hard-to-reach, biomarker-confirmed populations and notoriously slow screening.
View feasibility →Rheumatoid arthritis · Phase II–III
Rheumatoid arthritis
Rheumatoid arthritis has a well-established trial infrastructure, so feasibility turns on eligibility layering — prior biologic exposure, disease-activity thresholds, and washout requirements — more than on patient scarcity..
View feasibility →See a verdict you can actually check.
Send us a protocol. We'll return a fully cited feasibility verdict you can trace, line by line, back to public data — yours to white-label, defend in a bid, or hand to a regulator.